On May 8, 2025, the Court of Appeals for the Third Circuit affirmed the district court’s dismissal of AstraZeneca’s challenges to the Inflation Reduction Act’s Drug Price Negotiation Program and CMS’s Guidance implementing...more
5/16/2025
/ Administrative Procedure Act ,
Appeals ,
Article III ,
AstraZeneca ,
Centers for Medicare & Medicaid Services (CMS) ,
Constitutional Challenges ,
Drug Pricing ,
Inflation Reduction Act (IRA) ,
Judicial Review ,
Patents ,
Pharmaceutical Industry ,
Prescription Drugs ,
Standing